Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada.

摘要: Abstract Background Chronic lymphocytic leukemia (CLL) patients with 11q22.3 deletion (11q-) have an aggressive clinical course, and thus selection of first-line therapy in this group is important. This study aimed to improve our understanding real-world practice patterns outcomes CLL 11q- a population-based setting. Patients Methods The British Columbia Database was used identify 11q-. Overall survival (OS) treatment-free (TFS) were assessed after adjustment for prognostic factors. Results Of 1044 the database, 125 had (12%). Sixty-nine identified before initiation median OS TFS 14.7 (95% confidence interval [CI], 11.3-18.1) 2.5 CI, 1.5-3.6) years. Patient copresence 17p markedly worse prognosis, 4.9 versus years ( P  = .35). Conclusion Although cohort short at years, remains long even when most received initial treatment without alkylators.